The US Food and Drug Administration has said it is extending its reviewperiod for Myotrophin (mecasermin), the treatment for amyotrophic lateral sclerosis developed by US biotechnology firms Cephalon and Chiron, until November 11, 1997.
The review period was originally set to conclude this month, but the FDA has added the extra time in order to assess an ammendment to the New Drug Application recently filed by the two firms. Earlier this year, an FDA advisory panel issued a negative recommendation on the drug (Marketletters May 16 and 26).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze